Nancy LeaMond named Top Lobbyist by 'The Hill' newspaper

AARP Chief Advocacy and Engagement Officer Nancy LeaMond was recently named a 2017 Top Lobbyist by The Hill. 

This year, she is being recognized in the grass roots category, which includes a number of leading power players in the Nations Capital.

During her tenure at AARP, LeaMond has led several landmark campaigns, including: Take A Stand, You’ve Earned a Say, Health Action Now and Divided We Fail.

LeaMond is a nationally recognized leader in health, retirement security and other issues important to older Americans. Her career spans nearly 40 years in the government and nonprofit sectors.

She has been named by The Hill as one of the Top Lobbyists every year since 2011.

Search AARP Blogs

Related Posts
November 04, 2019 03:09 PM
To kick-off National Family Caregivers and Alzheimer's Awareness Month on November 1, AARP's Family and Caregiving Expert Amy Goyer appeared on NBC's TODAY Show with hosts Hoda Kotb and Maria Shriver to discuss the challenges of caring for someone with dementia. More than 16 million Americans provide unpaid care for people with Alzheimer's or other dementias. Goyer talked about the importance of planning, and offered tips on how caregivers can take care of themselves and deal with caregiver guilt. TODAY also posted a link to AARP's resources for caregivers on the show's website.
October 31, 2019 02:13 PM
Make no fossil bones about it—high prescription drug prices are monstrous but far from extinct. At AARP, we know drug costs shouldn’t be the scariest thing Americans face this Halloween. That’s why AARP let loose our drug-price-fighting Tyrannosaurus Rexes—known as the “Rx T. Rex”—for a national day of action this week to roar about the need to Stop Rx Greed.
October 08, 2019 09:29 AM
It’s well known that prescription drug prices are skyrocketing in America. Price increases for brand name drugs have far exceeded the rate of inflation since at least 2006, according to AARP’s Rx Price Watch report. And the average annual cost for just one brand name drug taken on a chronic basis was about $6,800 in 2017, almost $1,000 more than in 2015. However, it’s not just patients paying for greedy Big Pharma practices that keep drug prices high— it’s also taxpayers.